Norges Bank and Berkshire Hathaway Place $5.4B Combined New Stakes in UnitedHealth Group
Norges Bank opened a new $3.84B stake in UnitedHealth Group in Q2 and Berkshire Hathaway initiated a $1.57B position, while Chemistry Wealth Management increased its holdings by 59.2% to 16,199 shares worth $5.59M, making the stock its 18th largest holding. Morgan Stanley raised its price target to $395 with an overweight rating, RBC upped its target to $408 with an outperform rating, and UBS set a $430 buy objective, lifting the consensus price target to $385.54 across 29 analysts.
1. Institutional Investment Activity
Chemistry Wealth Management LLC increased its UnitedHealth Group stake by 59.2% during the third quarter, adding 6,022 shares to reach a total holding of 16,199 shares. This position represents approximately 1.1% of the firm’s total portfolio, making UNH its 18th largest holding. At quarter end, the fund’s UnitedHealth shares were valued at $5.59 million. Notable institutional moves in the same period include Norges Bank establishing a new position worth $3.84 billion, Berkshire Hathaway initiating a $1.57 billion stake, and Dodge & Cox more than doubling its holding to nearly 8.75 million shares after acquiring an additional 4.73 million shares. Overall, institutional investors now control close to 88% of UnitedHealth Group’s outstanding stock.
2. Analyst Commentary and Consensus Ratings
Several major research firms have reassessed UnitedHealth Group’s outlook in recent weeks. Morgan Stanley raised its assessment to overweight, Royal Bank of Canada upgraded to outperform, and UBS increased its rating to buy. Goldman Sachs initiated coverage with a buy recommendation, while Zacks Research moved the stock from strong sell to hold. Across all analysts, 17 currently recommend a buy, nine advise hold, and three suggest sell. The consensus view reflects a cautious middle ground, with analysts pointing to potential upside tied to margin expansion at Optum and continued strength in the core benefits business.
3. Quarterly Earnings Performance
For the quarter ended October 28th, UnitedHealth Group reported adjusted earnings per share of $2.92, surpassing the analyst estimate by $0.05. Revenue grew 12.2% year-over-year to $113.16 billion, in line with consensus forecasts. The company delivered a net margin of 4.04% and achieved a return on equity of 19.23%. Segment results were led by Optum’s services platforms, which saw double-digit growth, while UnitedHealthcare maintained stable medical loss ratios despite ongoing cost pressures in the commercial and Medicare Advantage lines.
4. Dividend and Capital Allocation
In mid-December, UnitedHealth Group paid its quarterly dividend of $2.21 per share to investors of record as of early December. This distribution annualizes to $8.84 per share, representing a payout ratio of approximately 46.1%. The company’s disciplined capital allocation framework balances steady dividend increases with opportunistic share repurchases, reflecting management’s commitment to returning cash while retaining firepower for strategic investments in technology and care delivery capabilities.